3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
41
Stomach Neoplasms
3
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Positive Breast Cancer
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
pazopanib
5
Doxorubicin
3
Bevacizumab
3
carotuximab
2
Sorafenib
2
Radiotherapy, Conformal
2
Paclitaxel
2
Gemcitabine
2
tremelimumab
1
trebananib
1
temsirolimus
1
talimogene laherparepvec
1
romidepsin
1
regorafenib
1
indolepropanol phosphate
1
eribulin
1
durvalumab
1
cixutumumab
1
Watchful Waiting
1
Vascular Endothelial Growth Factor A
1
TTI-621
1
Sunitinib
1
Sirolimus
1
Razoxane
1
Observation
1
Magnetic Resonance Spectroscopy
1
Ifosfamide
1
HhAntag691
1
Fluorodeoxyglucose F18
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Hemangiosarcoma
×
Ado-Trastuzumab Emtansine
×
Clear all
No trials found.